Seed Round

TwelveStone Health Partners and AI firm Tennr are teaming up to automate patient referrals, aiming to slash wait times and improve access to vital care.

A landmark $1.2M order for its advanced LineaDNA validates the firm's biotech arm, but can scientific success balance its new, volatile crypto strategy?

A new drug could redefine life for polycythemia vera patients, replacing frequent, burdensome blood draws with a simple weekly self-injection.

E-commerce logistics firm Globavend Holdings raised $1.4M in a direct offering, but its stock tumbled. A look at the deal, the market, and what's next.

The junior explorer has raised crucial capital to advance its drilling programs in Quebec's prolific gold belt, signaling strong investor confidence.

The popular brunch chain is betting on a digital marketing guru to transform its customer experience and accelerate growth in a tech-driven market.

The AI investment frenzy is shifting from GPUs to the physical world of power, cooling, and real estate, creating a new class of high-value companies.

Eight top US students will join a fully funded internship in Copenhagen to learn from Denmark's world-class sustainability, forging a new path for green careers.

Pharma giant GSK partners with biotech CAMP4, leveraging novel RNA-boosting tech to develop new therapies for neurodegenerative and kidney diseases.

New data reveals a stark split in private markets. Capital floods into infrastructure and AI, while concerns over PE exits and real estate persist.

SCALE AI's record funding fuels 44 new projects, aiming to accelerate homegrown AI and secure Canada's digital future amid fierce global competition.

Digital ad company Viewbix is acquiring Quantum X Labs, a deep-tech firm with a key patent in quantum error correction. Is this a visionary leap or a risky gamble?

A new partnership claims to power an AI with meditated 'love' from at-risk communities. Is this a bold new paradigm or a controversial social experiment?

A massive USD 300M investment in a Quebec copper foil plant is set to eliminate a critical EV battery vulnerability for North America. Here's why.

Palantir's DGSI contract renewal isn't just a deal; it's a story of strategic reliance, political tension, and the bedrock of its business model.

Serina Therapeutics poaches a top chemist to expand its POZ platform, signaling a major push beyond Parkinson's into new, high-value drug markets.

A new $50M fund says the old VC playbook is broken. We analyze if its AI-first model offers superior returns or is just a high-stakes bet on the future.

Nasdaq-listed Society Pass is ditching its e-commerce roots for the AI gold rush. Is this a savvy M&A masterstroke or a risky gamble in a capital-heavy arena?

Astellas Pharma's new deal with venture studio Autobahn Labs isn't just a partnership; it's a strategic overhaul of the R&D pipeline. Here's why.

RecycLiCo's new R&D hub is more than just a building; it's a strategic play in the high-stakes game of critical mineral independence.